

# **EHDN2021** Remote Meeting, Sep. 9 – 11

**Meeting Host: Patrick Weydt** 

THURSDAY, SEPTEMBER 9th, 2021	
14:00 - 14:30	WELCOME AND INTRODUCTION + EHDN Business (Constitution + Voting Results)
	Anne Rosser, Astri Arnesen, Patrick Weydt
14:30 - 15:00	KEYNOTE SESSION I: From fruit fly biorhythm genetics to Huntington's
	Charalambos P. Kyriacou
15:00 - 16:00	PLENARY SESSION I: Genetic modifiers of HD: DNA damage and somatic expansion of repeats
	Chaired by Lesley Jones and Davina Hensman
	1. Gene editing for expanded CAG/CTG repeat disorders: making a long story short
	Vincent Dion
	2. Using histone deacetylase 3 inhibition to rein in HD expansion mutations
	Bob Lahue
	3. Dissecting Genetic Modifiers of HD: Towards Understanding Mechanism
	Vanessa Wheeler
16:00 - 16:30	BREAK
16.30 - 16.35	Announcement: HDYO donation
	Matthew Ellison
16:35 - 17:35	PLENARY SESSION II: Cognition
	Chaired by Jamie Kulisevsky and Saul Martinez-Horta
	1. Session presentation
	Saul Martinez-Horta
	2. Visual system integrity in Huntington's disease
	Michael Orth
	3. Hippocampal-dependent memory in Huntington's disease
	Julie Stout
	4. Q&A
	5. Closing remarks
	Jaime Kulisevsky
17:35 - 18:35	SHORT COMMUNICATIONS I
17.55 - 10.55	Chaired by: Esther Cubo and Lauren Byrne
	chance by Esther case and Lauren by the
18:35 - 18:50	ROUND-UP and Goodbye for the day
	Host Patrick Weydt and guest(s) of the day
18:50-19:00	BREAK
19:00 - 20:00	POSTER SESSION: meet the poster presenter

Advancing Research, Conducting Trials, Improving Care

### FRIDAY, SEPTEMBER 10th, 2021

13:00-14:00 POSTER SESSION: meet the poster presenter

14:00 - 14:05 Announcement: MDS/EHDN teaching course

Michael Orth

14:05 - 15:35 PLENARY SESSION III: Clinical Trial Session

Chaired by: Ralf Reilmann and Dina de Sousa

1. Roche study update

Scott Schobel

2.SIGNAL/Vaccinex – results and lessons learnt

Maurice Zauderer

3. SELECT-HD, an adaptive first-in-human clinical trial to evaluate WVE-003, an investigational alleleselective mHTT-lowering oligonucleotide, in early manifest Huntington's disease

Vissia Viglietta

4. UniQure – An update on HD-GeneTRX-1 and HD-GeneTRX-2 - Phase 1 / 2 Clinical Trials of AMT-130 Gene Therapy for early stage HD

**David Cooper** 

5. Development of TTX-3360 to prevent onset and/or progression in HD and other Repeat Expansion Disorders by Halting Somatic Expansion

Irina Antonijevic

6. PROOF-HD – update on the status of the phase III clinical trial of pridopidine aiming to improve global function in early stage HD

Michael Hayden

15:35 - 15:45 BREAK

15:45 - 16:30 PANEL DISCUSSION: What are the lessons learned in the drug development process?

Chaired by: Ralf Reilmann and Dina de Sousa With the Speakers from Plenary Session III

16:30 - 16:45 BREAK

16:45 - 17:45 PARALLEL SESSIONS

**Neuro-Development** 

Chaired by: Sandrine Humbert and Silvia Gines

1. Huntington's disease alters cortical development in mouse and human Monia Barnat

2. Pediatric onset Huntington disease: neuro developmental delay or early

neurodegeneration?

Ferdinando Squitieri

3. Specific developmental alterations of striatal subpopulations in Huntington's disease

Josep Canals

Multidisciplinary care

Chaired by: Marleen van Walsem

and Ruth Veenhuizen

**1. Introduction:** Multidisciplinary care and treatment: focus on care in advanced stages: challenges and approaches for managing

2. Challenges and practice-based approaches in professional advanced care

Marleen van Walsem

**3. Neuro-affective approach in day-to-day care** Heidi Møller-Lund

4. Passivities of daily living

Manon van Kampen

5. Discussion

Advancing Research, Conducting Trials, Improving Care

#### 17:45 - 18:45 SHORT COMMUNICATIONS II

Chaired by: Ahmad Aziz and Maria Björkqvist

#### 18:45 - 19:00 ROUND-UP and Goodbye for the day

Host Patrick Weydt and guest(s) of the day

19:00 - 20:00 POSTER SESSION: meet the poster presenter

## SATURDAY, SEPTEMBER 11th, 2021

13:00 - 14:00 POSTER SESSION: meet the poster presenter

#### 14:00 - 15:00 SHORT COMMUNICATIONS III

Chaired by: Hoa Nguyen and Kathrin Reetz

#### 15:00 - 16:00 PARALLEL SESSIONS

# Digital Technologies to Advance Assessment and Care in HD

Chaired by Alzbeta Mühlbäck and Monica Busse

1. Introduction to the session: Landscape View of

the Field

Monica Busse

2. IDEA-FAST

Ralf Reilmann

3. eHealth Platform for HD overview

Pearl van Lonkhuizen

4. DOMINO-HD overview

Philippa Jones

5. Panel Discussion: Ethical & practical challenges

All speakers and chairs

16:00 - 16:15 BREAK

#### 16:15 - 17:45 PLENARY SESSION IV: Upcoming Clinical Trials

Chaired by: Jean-Marc Burgunder and Sarah Tabrizi

1. SOM Biotech

**TBD** 

2. Novartis

Beth Borowsky

3. Voyager

Maria Lopez-Bresnahan

**4. PTC** 

**Brian Pfister** 

5. Enroll-HD Platform Studies

Olivia Handley

6. HDClarity

Ed Wild

7. Panel discussion

all speakers from Plenary Session IV

# Sleep, circadian rhythm and metabolism in HD

Chaired by: Patrick Weydt and Asa Petersen

- 1. Introduction to the topic by the chairs
- 2. Sleep and metabolism in Huntington disease Roger Barker
- 3. Clock genes and circadian rhythm

Charalambos P. Kyriacou

4. Targeting cholesterol metabolism as a therapy for Huntington disease

therapy for Huntington disease

Sandrine Betuing

5. Summary and practical tips



17:45 - 18:00 BREAK

18:00 - 18:45 KEYNOTE SESSION II: Outlook

Chaired by: Dina de Sousa and Giorgos Papantoniou

New staging system in HD extending the window of testing and treatment

Swati Sathe

Q&A

18:45 - 19:15 ROUND-UP and Goodbye for the day

**Historical perspective** 

Tom Bird

Goodbye

Host Patrick Weydt with Astri Arnesen and Matthew Ellison